Expand JAGX Menu
JAGX MENU

JAGX Latest Press Releases

-- May 6, 2024 --

Crofelemer, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company's Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs ACCESSWIRE 8:32 AM

-- April 29, 2024 --

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID) ACCESSWIRE 8:31 AM

-- April 22, 2024 --

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care ACCESSWIRE 8:46 AM

-- April 18, 2024 --

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care ACCESSWIRE 8:41 AM

-- April 16, 2024 --

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care ACCESSWIRE 8:32 AM

-- April 9, 2024 --

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders ACCESSWIRE 4:16 PM

-- April 8, 2024 --

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement ACCESSWIRE 8:32 AM

-- April 2, 2024 --

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International ACCESSWIRE 8:54 AM

-- April 1, 2024 --

Jaguar Health Reports 2023 Financial Results ACCESSWIRE 8:02 AM

-- March 27, 2024 --

Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates ACCESSWIRE 8:31 AM

-- March 20, 2024 --

GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market ACCESSWIRE 8:32 AM

-- February 23, 2024 --

Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance ACCESSWIRE 8:32 AM

-- February 15, 2024 --

Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESSWIRE 8:32 AM

-- February 14, 2024 --

Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief ACCESSWIRE 8:32 AM

-- February 12, 2024 --

Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea ACCESSWIRE 8:32 AM

-- January 30, 2024 --

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions ACCESSWIRE 8:47 AM

-- January 29, 2024 --

Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference ACCESSWIRE 8:32 AM

-- January 25, 2024 --

Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD) ACCESSWIRE 8:33 AM

-- January 5, 2024 --

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACCESSWIRE 4:16 PM

-- January 4, 2024 --

Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) ACCESSWIRE 8:31 AM

-- December 11, 2023 --

A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II ACCESSWIRE 8:31 AM

-- December 7, 2023 --

MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company ACCESSWIRE 8:33 AM